Summit Therapeutics Inc. Investment Income, Nonoperating
Summit Therapeutics Inc. (SMMT) reported Investment Income, Nonoperating of $4.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-07-23
- Summit Therapeutics Inc. investment income, nonoperating for the quarter ending 2026-06-30 was $4.39M, a 47.13% increase year-over-year.
- Summit Therapeutics Inc. investment income, nonoperating for the quarter ending 2026-03-31 was $5.85M, a 51.52% increase year-over-year.
- Summit Therapeutics Inc. investment income, nonoperating for the quarter ending 2025-12-31 was $5.88M, a 24.50% increase year-over-year.
- Summit Therapeutics Inc. investment income, nonoperating for the quarter ending 2025-09-30 was $2.78M, a 35.90% decline year-over-year.
- Summit Therapeutics Inc. investment income, nonoperating for fiscal 2025 was $15.50M, a 15.11% increase from fiscal 2024.
- Summit Therapeutics Inc. investment income, nonoperating for fiscal 2024 was $13.47M, a 29.44% increase from fiscal 2023.
- Summit Therapeutics Inc. investment income, nonoperating for fiscal 2023 was $10.40M, a 587.57% increase from fiscal 2022.
- Summit Therapeutics Inc. investment income, nonoperating for fiscal 2022 was $1.51M.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.39M 10-Q · filed 2026-07-23 | $10.24M 10-Q · filed 2026-07-23 | $16.11M derived: sum of 3 quarters · filed 2026-07-23 | $18.89M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $5.85M 10-Q · filed 2026-04-30 | $11.73M derived: sum of 2 quarters · filed 2026-04-30 | $14.51M derived: sum of 3 quarters · filed 2026-04-30 | $17.49M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.66M derived: sum of 2 quarters · filed 2026-02-23 | $11.64M derived: sum of 3 quarters · filed 2026-07-23 | $15.50M 10-K · filed 2026-02-23 |
| 2025-09-30 | $2.78M 10-Q · filed 2025-10-20 | $5.76M derived: sum of 2 quarters · filed 2026-07-23 | $9.62M 10-Q · filed 2025-10-20 | $14.34M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $2.98M 10-Q · filed 2026-07-23 | $6.84M 10-Q · filed 2026-07-23 | $11.56M derived: sum of 3 quarters · filed 2026-07-23 | $15.90M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $3.86M 10-Q · filed 2026-04-30 | $8.58M derived: sum of 2 quarters · filed 2026-04-30 | $12.92M derived: sum of 3 quarters · filed 2026-04-30 | $15.50M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $9.06M derived: sum of 2 quarters · filed 2026-02-23 | $11.64M derived: sum of 3 quarters · filed 2026-02-23 | $13.47M 10-K · filed 2026-02-23 |
| 2024-09-30 | $4.34M 10-Q · filed 2025-10-20 | $6.92M derived: sum of 2 quarters · filed 2025-10-20 | $8.74M 10-Q · filed 2025-10-20 | $11.12M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $2.58M 10-Q · filed 2025-08-11 | $4.41M 10-Q · filed 2025-08-11 | $6.78M derived: sum of 3 quarters · filed 2026-02-23 | $9.27M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $1.83M 10-Q · filed 2025-05-01 | $4.20M derived: sum of 2 quarters · filed 2026-02-23 | $6.69M derived: sum of 3 quarters · filed 2026-02-23 | $9.97M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $4.86M derived: sum of 2 quarters · filed 2026-02-23 | $8.15M derived: sum of 3 quarters · filed 2026-02-23 | $10.40M 10-K · filed 2026-02-23 |
| 2023-09-30 | $2.48M 10-Q · filed 2024-10-30 | $5.77M derived: sum of 2 quarters · filed 2024-10-30 | $8.03M 10-Q · filed 2024-10-30 | $9.04M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | $3.29M 10-Q · filed 2024-08-06 | $5.54M 10-Q · filed 2024-08-06 | $6.56M derived: sum of 3 quarters · filed 2025-02-24 | $6.56M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $1.76M 10-Q · filed 2024-05-01 | $3.27M derived: sum of 2 quarters · filed 2025-02-24 | $3.27M derived: sum of 3 quarters · filed 2025-02-24 | $3.27M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $1.51M derived: sum of 2 quarters · filed 2025-02-24 | $1.51M derived: sum of 3 quarters · filed 2025-02-24 | $1.51M 10-K · filed 2025-02-24 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |